High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)’s ratings from Peer Perform, with Wolfe assigning them similar $300 price targets. The firm’s logic in each case was based on a comparable set of factors: pipelines that the market appears to […]
Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 pushes well beyond what Wall Street consensus currently projects, and the catalysts behind each target may surprise you.
Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
AbbVie still looks like a compelling buy at its all-time high.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
AbbVie’s model fair value is held at US$253.55 per share, signaling no change to the core price target after factoring in the proposed Apogee Therapeutics acquisition. Research around the US$10.9b deal points to a split view, with some analysts highlighting the immunology and atopic dermatitis opportunity, while others question how much value the company can capture against rising competition. As you read on, you will see how these mixed signals are shaping the evolving AbbVie story and what...
AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight rating on the company’s shares. The firm mentioned AbbVie’s extensive inflammatory bowel disease pipeline as a major source of investor interest. AbbVie Inc. […]
AbbVie Inc. (NYSE:ABBV) is included among the Top 12 Undervalued Dividend Stocks to Buy Now. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. On May 15, Evercore ISI slightly trimmed its price target on AbbVie Inc. (NYSE:ABBV) from $236 […]
Realty Income (NYSE:O) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing to its 113th consecutive quarterly dividend increase as proof you can collect a check and tune out the rest of the market. The underlying numbers tell a different story. The Math On O Has Quietly Broken O trades at ... Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
